Afatinib (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Afatinib" in Italian language version.

refsWebsite

Global rank Italian rank

9nih.gov

4^th place

9^th place

7doi.org

2^nd place

7^th place

5oadoi.org

799^th place

22^nd place

1fda.gov

447^th place

644^th place

1tga.gov.au

3,984^th place

low place

1medicines.org.uk

3,823^rd place

low place

1web.archive.org

1^st place

1medscape.com

719^th place

799^th place

1clinicaltrials.gov

5,225^th place

5,296^th place

1businesswire.com

615^th place

1,092^nd place

businesswire.com

Afatinib (BIBW 2992*) Triples Progression Free Survival in Phase III Study in Lung Cancer Patients, su businesswire.com, BusinessWire, 11 ottobre 2010.

clinicaltrials.gov

Clinical trial number NCT01085136 for "LUX-Lung 5: BIBW 2992 Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following BIBW 2992 Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib" at ClinicalTrials.gov

doi.org

dx.doi.org

Role of afatinib in the treatment of advanced lung squamous cell carcinoma, in Clinical Pharmacology, vol. 9, 2017, pp. 147–157, DOI:10.2147/CPAA.S112715, PMID 29225480.
Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, et al., A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab, in Breast Cancer Research and Treatment, vol. 133, n. 3, Giugno 2012, pp. 1057–65, DOI:10.1007/s10549-012-2003-y, PMC 3387495, PMID 22418700.
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, in Oncogene, vol. 27, n. 34, Agosto 2008, pp. 4702–11, DOI:10.1038/onc.2008.109, PMID 18408761.
Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al., Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial, in The Lancet. Oncology, vol. 13, n. 5, Maggio 2012, pp. 528–38, DOI:10.1016/S1470-2045(12)70087-6, PMID 22452896.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, in The Lancet. Oncology, vol. 16, n. 2, February 2015, pp. 141–51, DOI:10.1016/s1470-2045(14)71173-8, PMID 25589191.
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs, in Clinical Cancer Research, vol. 21, n. 23, Dicembre 2015, pp. 5305–13, DOI:10.1158/1078-0432.CCR-15-1046, PMID 26206867.
Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, et al., A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer, vol. 134, n. 3, Agosto 2012, pp. 1149–59, DOI:10.1007/s10549-012-2126-1, PMC 3409367, PMID 22763464.

fda.gov

Afatinib, su fda.gov, US Food and Drug Administration, 12 luglio 2013.

medicines.org.uk

Giotrif 20 mg film-coated tablets – Summary of Product Characteristics (SPC), su electronic Medicines Compendium, Boehringer Ingelheim Limited, 20 gennaio 2014. URL consultato il 28 gennaio 2014.

medscape.com

reference.medscape.com

Gilotrif (afatinib) dosing, indications, interactions, adverse effects, and more, su Medscape Reference, WebMD. URL consultato il 28 gennaio 2014.

nih.gov

ncbi.nlm.nih.gov

Minkovsky N, Berezov A, BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors, in Current Opinion in Investigational Drugs, vol. 9, n. 12, Dicembre 2008, pp. 1336–46, PMID 19037840.
Role of afatinib in the treatment of advanced lung squamous cell carcinoma, in Clinical Pharmacology, vol. 9, 2017, pp. 147–157, DOI:10.2147/CPAA.S112715, PMID 29225480.
Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, et al., A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab, in Breast Cancer Research and Treatment, vol. 133, n. 3, Giugno 2012, pp. 1057–65, DOI:10.1007/s10549-012-2003-y, PMC 3387495, PMID 22418700.
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, in Oncogene, vol. 27, n. 34, Agosto 2008, pp. 4702–11, DOI:10.1038/onc.2008.109, PMID 18408761.
Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al., Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial, in The Lancet. Oncology, vol. 13, n. 5, Maggio 2012, pp. 528–38, DOI:10.1016/S1470-2045(12)70087-6, PMID 22452896.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, in The Lancet. Oncology, vol. 16, n. 2, February 2015, pp. 141–51, DOI:10.1016/s1470-2045(14)71173-8, PMID 25589191.
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs, in Clinical Cancer Research, vol. 21, n. 23, Dicembre 2015, pp. 5305–13, DOI:10.1158/1078-0432.CCR-15-1046, PMID 26206867.
Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, et al., A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer, vol. 134, n. 3, Agosto 2012, pp. 1149–59, DOI:10.1007/s10549-012-2126-1, PMC 3409367, PMID 22763464.

dailymed.nlm.nih.gov

GILOTRIF (afatinib) tablet, film coated [Boehringer Ingelheim Pharmaceuticals, Inc.], su DailyMed, Boehringer Ingelheim Pharmaceuticals, Inc., Novembre 2013. URL consultato il 28 gennaio 2014.

oadoi.org

Role of afatinib in the treatment of advanced lung squamous cell carcinoma, in Clinical Pharmacology, vol. 9, 2017, pp. 147–157, DOI:10.2147/CPAA.S112715, PMID 29225480.
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, in Oncogene, vol. 27, n. 34, Agosto 2008, pp. 4702–11, DOI:10.1038/onc.2008.109, PMID 18408761.
Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al., Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial, in The Lancet. Oncology, vol. 13, n. 5, Maggio 2012, pp. 528–38, DOI:10.1016/S1470-2045(12)70087-6, PMID 22452896.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, in The Lancet. Oncology, vol. 16, n. 2, February 2015, pp. 141–51, DOI:10.1016/s1470-2045(14)71173-8, PMID 25589191.
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs, in Clinical Cancer Research, vol. 21, n. 23, Dicembre 2015, pp. 5305–13, DOI:10.1158/1078-0432.CCR-15-1046, PMID 26206867.

tga.gov.au

ebs.tga.gov.au

GIOTRIF® Afatinib (as afatinib dimaleate), su TGA eBusiness Services, Boehringer Ingelheim Pty Limited, 7 novembre 2013. URL consultato il 28 gennaio 2014.

web.archive.org

Giotrif : EPAR -Product Information (PDF), su European Medicines Agency, Boehringer Ingelheim International GmbH, 16 ottobre 2013. URL consultato il 28 gennaio 2014 (archiviato dall'url originale il 4 febbraio 2014).